Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with procedures ...

An NHS patient waited over 400 days to start investigations for suspected prostate cancer. Another Scot waited 352 days with ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Today, a patient diagnosed with advanced prostate cancer has options. Doctors can offer a suite of androgen-suppressing drugs to extend his life. There are genetic tests that can show whether he’s a ...

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

Cancer of the prostate has become the leading cause of cancer diagnoses among males in the United Kingdom. Its treatment, ...

The marathon session, conducted on January 1 from 8 am to 5 pm, was led by Prof Santosh Kumar, head of the urology team.

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

Plans for a new NHS service being called an 'online hospital' have been unveiled - here's when patients are due to use it and ...